Population Pharmacokinetics of Paracetamol in Overweight and Obese Children

Inclusion Criteria: * Child aged 6 to 17 inclusive with normal weight for age and gender (body mass index \[BMI\]\<25kg/m2 adult equivalent at 18 years \[IOTF 25\]), overweight (body mass index \[BMI\]≥ 25kg/m2 adult equivalent at age 18 \[IOTF 25\] and obese (BMI ≥ 30kg/m2 adult equivalent at age 18 \[IOTF 30\]) for age and sex * Surgical procedure requiring treatment with paracetamol intravenously as an analgesic * No opposition by the holder(s) of parental authority Exclusion Criteria: * History of chronic anaemia (≤ 5g/100ml) * History of hepatocellular insufficiency (ASAT, ALAT ≥ 3N) * History of renal impairment (\<60mL/min\*1.73m2) * History of Gilbert's disease * History of Type 2 diabetes * Major motor or neurological disability * Intake of paracetamol within 24 hours before study inclusion (injection of paracetamol IV or oral intake) * Patients treated with medicinal products known to affect CYP2E1 or UGT (UDP glucuronosyltransferase): isoniazid, antiepileptic drugs (carbamazepine, phenytoin or phenobarbital), antiretroviral and tyrosine kinase inhibitors